HONG KONG – Astrazeneca plc has won two new approvals from Japan's PMDA for its Lynparza (olaparib) in breast cancer as well as chemotherapy maintenance drug Imfinzi (durvalumab), a further sign that the country is getting faster in approving these drugs, reflecting an urgency in accessing newer cancer treatments.
HONG KONG – Lupin Ltd. and Mylan NV will be working together on commercializing a biosimilar Enbrel (etanercept) drug, or YLB-113, in a deal that brings Lupin an up-front payment of $15 million and potential commercial milestones together with an equal share in net profits of the product.
HONG KONG – Lupin Ltd. and Mylan NV will be working together on commercializing a biosimilar Enbrel (etanercept) drug, or YLB-113, in a deal that brings Lupin an up-front payment of $15 million and potential commercial milestones together with an equal share in net profits of the product.
HONG KONG – Xian Janssen Pharmaceutical Ltd. has launched Simponi (golimumab injection), making it the first once-monthly self-injectable anti-TNF biologic for patients with active ankylosing spondylitis (AS) in China.
HONG KONG – Xian Janssen Pharmaceutical Ltd. has launched Simponi (golimumab injection), making it the first once-monthly self-injectable anti-TNF biologic for patients with active ankylosing spondylitis (AS) in China.
